ASX:RGS

Regeneus Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume13,076 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive RGS News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneus and its competitors with MarketBeat's FREE daily newsletter.


About Regeneus

Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases. Its lead platform technology includes Progenza, a cryopreserved multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was founded in 2007 and is headquartered in Paddington, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Regeneus (ASX:RGS) Frequently Asked Questions

What stocks does MarketBeat like better than Regeneus?

Wall Street analysts have given Regeneus a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regeneus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Regeneus' key executives?

Regeneus' management team includes the following people:
  • Prof. Graham Vesey Ph.D., Chief Scientific Officer & Exec. Director (Age 56, Pay $171.34k)
  • Mr. Karolis Rosickas, Chief Exec. Officer
  • Dr. Charlotte Morgan Ph.D., Head of R&D

Who are some of Regeneus' key competitors?

What is Regeneus' stock symbol?

Regeneus trades on the ASX under the ticker symbol "RGS."

How much money does Regeneus make?

Regeneus has a market capitalization of $0.00 and generates $7.96 million in revenue each year.

How many employees does Regeneus have?

Regeneus employs 9,000 workers across the globe.

What is Regeneus' official website?

The official website for Regeneus is regeneus.com.au.

Where are Regeneus' headquarters?

Regeneus is headquartered at 3701 Wayzata Blvd, Minneapolis, Minnesota 55416.

How can I contact Regeneus?

Regeneus' mailing address is 3701 Wayzata Blvd, Minneapolis, Minnesota 55416. The company can be reached via phone at 61 2 9499 8010.


This page was last updated on 9/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.